1. PARP-1 Overexpression as an Independent Prognostic Factor in Adult Non-M3 Acute Myeloid Leukemia
    Hossein Pashaiefar et al, 2018, Genetic Testing and Molecular Biomarkers CrossRef
  2. Overexpression of CLC-3 is regulated by XRCC5 and is a poor prognostic biomarker for gastric cancer
    Zhuoyu Gu et al, 2018, J Hematol Oncol CrossRef
  3. Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis
    Amilcar Barreta et al, 2018, Human Pathology CrossRef
  4. Regorefenib induces extrinsic/intrinsic apoptosis and inhibits MAPK/NF-κB-modulated tumor progression in bladder cancer in vitro and in vivo.
    Chih-Hung Chiang et al, 2019, Environ Toxicol CrossRef
  5. NAD+ Metabolism in Aging and Cancer
    Tyler G. Demarest et al, 2019, Annu. Rev. Cancer Biol. CrossRef
  6. Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities
    Jyotika Rajawat et al, 2017, Med. Res. Rev. CrossRef
  7. In vitro selective cytotoxicity of the dietary chalcone cardamonin (CD) on melanoma compared to healthy cells is mediated by apoptosis
    Lena Berning et al, 2019, PLoS ONE CrossRef
  8. Precision medicine in gastric cancer.
    Patrizia Bonelli et al, 2019, World J Gastrointest Oncol CrossRef
  9. Multifaceted Role of PARP-1 in DNA Repair and Inflammation: Pathological and Therapeutic Implications in Cancer and Non-Cancer Diseases
    Simonetta Pazzaglia et al, 2019, Cells CrossRef
  10. PARP1 V762A polymorphism affects the prognosis of myelodysplastic syndromes
    Nanami Gotoh et al, 2020, Eur J Haematol CrossRef
  11. Positive Helicobacter pylori status is associated with better overall survival for gastric cancer patients: evidence from case-cohort studies
    Xuqian Fang et al, 2017, Oncotarget CrossRef
  12. PARP-1 promotes tumor recurrence after warm ischemic liver graft transplantation via neutrophil recruitment and polarization
    Shuai Wang et al, 2017, Oncotarget CrossRef
  13. Combining PARP and DNA-PK Inhibitors With Irradiation Inhibits HPV-Negative Head and Neck Cancer Squamous Carcinoma Growth
    Ling Zeng et al, 2020, Front. Genet. CrossRef
  14. Inhibition of DNA Repair in Cancer Therapy: Toward a Multi-Target Approach
    Samuele Lodovichi et al, 2020, IJMS CrossRef
  15. An assessment of poly (ADP‐ribose) polymerase‐1 role in normal and cancer cells
    Manoj Kumar et al, 2020, BioFactors CrossRef
  16. The Prognostic Values of PARP-1 Expression in Uveal Melanoma
    Malgorzata Gajdzis et al, 2021, Cells CrossRef
  17. DNA Damage Response in Multiple Myeloma: The Role of the Tumor Microenvironment
    Takayuki Saitoh et al, 2021, Cancers CrossRef
  18. PARP1 rs1136410 C/C genotype associated with an increased risk of esophageal cancer in smokers
    Rongmiao Zhou et al, 2021, Mol Biol Rep CrossRef
  19. Pinus kesiya Royle ex Gordon induces apoptotic cell death in hepatocellular carcinoma HepG2 cell via intrinsic pathway by PARP and Topoisomerase I suppression
    Piman Pocasap et al, 2021, Biomedicine & Pharmacotherapy CrossRef
  20. Novel Tracers and Radionuclides in PET Imaging
    Christian Mason et al, 2021, Radiologic Clinics of North America CrossRef
  21. PARP1 as a prognostic biomarker for human cancers: a meta-analysis
    Yan-Hua Huang et al, 2021, Biomarkers in Medicine CrossRef
  22. PARP5B is required for nonhomologous end joining during tumorigenesis in vivo
    Jianchun Wu et al, 2021, Molecular Carcinogenesis CrossRef
  23. High Poly(ADP-Ribose) Polymerase Expression Does Relate to Poor Survival in Solid Cancers: A Systematic Review and Meta-Analysis
    Nishant Thakur et al, 2021, Cancers CrossRef
  24. Pleiotropic role of PARP1: an overview
    Vikas Kumar et al, 2022, 3 Biotech CrossRef
  25. Positive H. pylori status predicts better prognosis of non-cardiac gastric cancer patients: results from cohort study and meta-analysis
    Zhifang Jia et al, 2022, BMC Cancer CrossRef
  26. Oxidative Stress Markers Are Associated with a Poor Prognosis in Patients with Pancreatic Cancer
    Miguel A. Ortega et al, 2022, Antioxidants CrossRef
  27. PARG suppresses tumorigenesis and downregulates genes controlling angiogenesis, inflammatory response, and immune cell recruitment
    Sarah Johnson et al, 2022, BMC Cancer CrossRef
  28. Upregulation of PARG in prostate cancer cells suppresses their malignant behavior and downregulates tumor-promoting genes
    Yaroslava Karpova et al, 2022, Biomedicine & Pharmacotherapy CrossRef
  29. Identification of a new member of Mortaparib class of inhibitors that target mortalin and PARP1
    Hazna Noor Meidinna et al, 2022, Front. Cell Dev. Biol. CrossRef
  30. An electrostatic force-independent dephosphorylation-driven chemiluminescent biosensor for sensitive and rapid detection of poly(ADP-ribose) polymerase-1 in human breast tissues
    Ming-hao Liu et al, 2023, Chemical Engineering Journal CrossRef
  31. Regulation of Biomolecular Condensates by Poly(ADP-ribose)
    Kevin Rhine et al, 2023, Chem. Rev. CrossRef
  32. Exploring the Potential Mechanism of Action of Ursolic Acid against Gastric Cancer and COVID-19 using Network Pharmacology and Bioinformatics Analysis
    Zhiyao Liu et al, 2023, CPD CrossRef
  33. Exploring homologous recombination repair and base excision repair pathway genes for possible diagnostic markers in hematologic malignancies
    Sumaira Fida Abbasi et al, 2023, Mol Genet Genomics CrossRef
  34. Mutual regulation of TGFβ-induced oncogenic EMT, cell cycle progression and the DDR
    Harald Schuhwerk et al, 2023, Seminars in Cancer Biology CrossRef
  35. Disrupting Poly(ADP-ribosyl)ating Pathway Creates Premalignant Conditions in Mammalian Liver
    Yaroslava Karpova et al, 2023, IJMS CrossRef
  36. Studies on the mechanism of local and extra-intestinal tissue manifestations in AOM-DSS-induced carcinogenesis in BALB/c mice: role of PARP-1, NLRP3, and autophagy
    Shivani Singla et al, 2023, Naunyn-Schmiedeberg's Arch Pharmacol CrossRef
  37. A review of poly(ADP-ribose)polymerase-1 (PARP1) role and its inhibitors bearing pyrazole or indazole core for cancer therapy
    Inês M. Bastos et al, 2024, Biochemical Pharmacology CrossRef
  38. PARP-1 selectively impairsKRAS-driven phenotypic and molecular features in intrahepatic cholangiocarcinoma
    Friederike L Keggenhoff et al, 2024, Gut CrossRef